文献速递MDS 与骨髓增殖性肿瘤白血病造血干细胞移植与细胞治疗

管理难以管理者:针对TP53突变型骨髓增生异常肿瘤和急性髓系白血病真实世界患者原型的循证方法

Managing the unmanageable: evidence-driven approaches to real-world patient prototypes of TP53-mutant myelodysplastic neoplasms and acute myeloid leukemia.
PubMed 文献 · Leukemia · 2024-09-30

该综述以临床病例为基础,汇总指导TP53突变型MDS和AML常见患者原型管理的关键数据,讨论一线治疗选择、异基因干细胞移植的争议,以及eprenetapopt、magrolimab、sabatolimab和idasanutlin等领先在研药物临床试验暂停后的应对思路。

要点

  • TP53突变型MDS和AML对常规化疗耐药或复发,目前尚无靶向治疗获批。
  • 管理方案常由临床判断和医生偏好驱动,而非严格循证共识指南。
  • 综述讨论一线选择如何针对异质性患者群体优化,并总结异基因移植争议。

核心结论

  • TP53突变型MDS和AML管理困难源于对常规化疗耐药或复发及靶向TP53突变细胞的研究性治疗转化有限。
  • 目前尚无靶向治疗获批用于该突变亚组,管理方案常由临床判断和/或医生偏好驱动而非严格循证共识指南。

研究设计与样本

  • 临床病例为基础、循证驱动的综述,汇总指导常见患者原型管理的最显著数据。

主要发现

  • 讨论源自多机构经验和疾病中心联盟的一线治疗选择菜单,以及如何针对异质性患者群体优化这些一线选择。
  • 总结关于是否应为这些患者提供异基因干细胞移植的争议。
  • 探讨eprenetapopt、magrolimab、sabatolimab和idasanutlin等领先在研药物临床试验暂停的不利消息,并提出2025年重振精准治疗管线的解决方案。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with TP53 aberrations comprise the highest risk subset of all myeloid malignancies. The managerial conundrum of TP53-mutant myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML) stems from refractoriness to or relapse after conventional chemotherapy, as well as the limited translational success of investigational therapies targeting TP53-mutant cells. Thus far, no targeted therapies have been commercially approved for this mutational subset. As a result, management plans for patients with TP53-mutant MDS and AML are often driven by clinical judgment and/or physician preference rather than consensus guidelines backed by a rigorous evidence basis. This clinical case-based, evidence-driven review highlights the most salient data that guides the management of commonly encountered patient prototypes. This review discusses the therapeutic menu of first-line options that derive from multi-institutional experiences as well as from disease-centric consortia and discusses how these first-line options can be optimally tailored to heterogeneous groups of patients. The debate regarding whether allogeneic stem cell transplant should be offered to these patients is summarized. Finally, this review explores the recent unfortunate news of pauses in clinical trials for the leading investigational agents - eprenetapopt, magrolimab, sabatolimab, and idasanutlin - and offers solutions toward re-invigorating the pipeline of precision therapeutics in 2025.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Patel SA. Managing the unmanageable: evidence-driven approaches to real-world patient prototypes of TP53-mutant myelodysplastic neoplasms and acute myeloid leukemia. Leukemia. 2024. PMID: 39349613. doi:10.1038/s41375-024-02417-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。